- Incyte drops early-stage JAK2 inhibitor to prioritize next-generation pipelineIncyte announced it is terminating development of its early-stage oral JAK2 inhibitor, INCB160058, after a Phase 1 study in myeloproliferative neoplasms. The company said the decision reflects the…
- Biotech earnings season kicks off as Agios reports Phase 2 setback for sickle-cell drugThe second‑quarter earnings window has begun, and analysts are zeroing in on a handful of biotech companies with high‑profile catalysts. Smaller biotechs are increasingly opting to launch their pr…